[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579510":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":44,"collaborators":7,"id":46,"slug":7,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":66,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Charline Vauchy, PhD.","CONTACT","+33381218875","cvauchy@chu-besancon.fr",[15,32],{"facility":16,"status":7,"city":17,"state":7,"zip":18,"country":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"Besançon University Hospital","Besançon","25000","France",{"type":21,"coordinates":22},"Point",[23,24],6.01815,47.24878,{"lat":24,"lon":23},[27,29],{"name":28,"role":11,"phone":7,"phoneExt":7,"email":7},"Charline Vauchy, PhD",{"name":30,"role":31,"phone":7,"phoneExt":7,"email":7},"Melchior Chabannes, MD.","PRINCIPAL_INVESTIGATOR",{"facility":33,"status":7,"city":34,"state":7,"zip":35,"country":19,"cosmosGeoPoint":36,"geoPoint":40,"contacts":41},"Tours University Hospital","Tours","37044",{"type":21,"coordinates":37},[38,39],0.70398,47.39484,{"lat":39,"lon":38},[42],{"name":43,"role":31,"phone":7,"phoneExt":7,"email":7},"Bénédicte Sautenet, Prof.",{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100579510",false,"NCT06825234","Prognostic Value of a Multidimensional Assessment for Survival in Elderly Patients With CKD 4B\u002F5","PROFILER","Inclusion Criteria:\n\n* Patients with CKD stage 4B or 5 (first consultation with GFR \\\u003C 20 mL\u002Fmin \u002F1.73 m2 in CKD-EPI 2009).\n* Fluency in French\n* Membership of a French social security scheme\n* Non-opposition from the subject to participate in the study\n\nExclusion Criteria:\n\n* Subjects with limited legal capacity.\n* Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.\n* Subjects with no social security coverage.\n* Subjects judged by the investigator to be unlikely to comply with study procedures\n* Subjects unable to understand the reasons for the study; psychiatric disorders judged by the investigator to be incompatible with inclusion in the study.","ALL","75 Years",{"count":55,"type":56},390,"ESTIMATED","OBSERVATIONAL","The aim of this study is to determine a multidimensional signature (integrating frailty and patient-reported outcomes measures (PROMs) at entry into stage 4B\u002F5 CKD) to improve prediction of renal death (dialysis, transplantation, conservative management, death).",[60,61],"Chronic Kidney Disease Stage 5","Chronic Kidney Disease Stage 4B",[63,64,65],"Frailty","Patient-Related Outcomes","Personalised care","NOT_YET_RECRUITING","2025-04-30",{"date":69,"type":70},"2025-05-01","ACTUAL",{"date":72,"type":56},"2025-06",{"date":74,"type":56},"2028-12",{"name":5,"class":6},2]